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Abstract
Background: This paper describes about a study protocol of phase I/II multicenter prospective clinical trial
evaluating the feasibility and efficacy of the hybrid of intracavitary and interstitial brachytherapy (HBT) for locally
advanced uterine cervical cancer patients.
Methods and design: Patients with histologically confirmed FIGO stage IB2, IIA2, IIB, and IIIB uterine cervical
carcinoma width of which is larger than 5 cm assessed by MRI will be entered to this clinical trial. Protocol therapy
is 30-30.6 Gy in 15-17 fractions of whole pelvic radiotherapy concurrent with weekly CDDP (40 mg/m2), followed by
24 Gy in 4 fractions of HBT and central shield EBRT up to 50-50.4 Gy in 25-28 fractions. Tumor width is assessed
again within one week before the first HBT and if the tumor width is larger than 4 cm, patients proceed to the
secondary registration. In phase I section, feasibility of this will be investigated. If less than 10 % out of 20 patients
experienced greater than grade 3 acute non-hematologic adverse effects, the study proceeds to phase II part. In
phase II part a total of 55 patients will be accrued and the efficacy of the HBT will be investigated comparing with
historical control data. If the lower margin of 90 % confidence interval of the 2-year pelvic progression-free survival
of the HBT trial is higher than 64 %, the HBT is considered to be more effective than conventional ICBT.
Discussion: The aim of this study is to demonstrate the feasibility and efficacy of the HBT for locally advanced
cervical cancer. This trial will clarify the indication, feasibility, and efficacy of this new technique.
Trial registration: UMIN000019081; Registration date: 2015/9/30
Keywords: Uterine cervical cancer, Hybrid of intracavitary and interstitial brachytherapy, A prospective clinical trial
protocol
Background
Standard primary radiation therapy for locally advanced
cervical cancer is the combination of external beam radi-
ation therapy (EBRT) and intracavitary brachytherapy
(ICBT) with cisplatin based concurrent chemotherapy
[1–5]. The classical ICBT [6] is based on the Manchester
system [7, 8] or the Paris system [9], in which ICBT
applicators consist of intrauterine (tandem) and vaginal
source (ovoid or ring). This system has been used as the
standard method for several decades. Although the
Manchester method has been used for long time and fa-
vorable clinical results were reported so far [10–13], this
system has a drawback; because the Manchester system
was developed about a half century before, this system
was based on two-dimensional, point-based system and
used orthogonal x-ray images for dose calculation. The
prescribed dose is delivered to a certain fixed reference
point, point A, and this point is used independent of
each tumor size or shape. Therefore, excellent tumor
control can be expected for small tumors, while rela-
tively high relapse rate was reported for large tumors
part of which could not be covered by prescribed dose
[14–16].
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In locally advanced cervical cancer, tumors tend to
spread laterally along with the cardinal ligament.
Therefore, it was supposed to add a few interstitial
needles in this region that would contribute to im-
prove dose coverage and tumor control [17, 18]. Sev-
eral positive clinical results have been reported
concerning the hybrid of intracavitary and interstitial
brachytherapy (HBT) for locally advanced cervical
cancer [19, 20]. On the other hand, it was stated in
the American Brachytherapy Society consensus guide-
lines that in a situation of poorly fitting intracavitary
applicators, large lesions, and lower vaginal involve-
ment interstitial brachytherapy (ISBT) should be con-
sidered [21]. There are overlaps of indication between
ICBT alone, HBT, and ISBT alone and so far there
exists no universal guideline for the indication of
HBT and no prospective clinical trial focusing only
on HBT for locally advanced cervical cancer.
The aim of this clinical trial is to investigate the feasi-
bility, reproducibility, and efficacy of HBT for locally ad-
vanced cervical cancer who undergo primary
chemoradiotherapy.
Methods/design
Study design
The HBT trial is a multi-institutional prospective
phase I/II study. Figure 1 depicts the study workflow.
Previously untreated patients with FIGO stage IB2,
IIA2, IIB, and IIIB uterine cervical cancer with width
of the tumor is larger than 5 cm assessed by MRI
and who met the following inclusion criteria and who
provided written informed consent proceeded to the
initial registration. FIGO IVA disease is excluded
because in FIGO IVA, tumor invades directly into
adjacent rectum or bladder and additional interstitial
needles into the rectum or the bladder are expected
to cause more frequent acute non-hematologic ad-
verse effects than other stages. Figure 2 shows over-
view of the protocol treatment. After receiving 30-
30.6 Gy in 15-17 fractions of whole pelvic radiother-
apy concurrent with weekly CDDP (40 mg/m2),
24 Gy in 4 fractions of HBT and central shield EBRT
up to 50-50.4 Gy in 25-28 fractions are started.
Tumor width is assessed within one week before the
first HBT and in case of the tumor width is larger
than 4 cm, patients proceeded to the secondary
registration.
Figure 3 shows the stages of the HBT study. First
20 patients who proceeded to the secondary registra-
tion will be enrolled in phase I part and the safety
and tolerability of the HBT will be investigated. If less
than 2 out of 20 patients (10 %) develop Grade 3 or
higher acute non-hematological adverse effects, the
HBT study proceeds to phase II part. In phase II part,
2-year pelvic progression-free survival is compared
with historical control. Historical control data is cited
from the publication of Pötter et al. [22] which dem-
onstrated that 2-year pelvic progression-free survival
rate of 64 % for patients with uterine cervical cancer
whose initial tumor size was larger than 5 cm and
were treated with conventional ICBT. Therefore, if
the lower margin of 90 % confidence interval of the
2-year pelvic progression-free survival of the HBT
trial is higher than 64 %, the HBT is considered to be
more effective than conventional ICBT.
Endpoints
The primary endpoint of this study in phase I part and
in phase II part is the rate of acute non-hematologic
Fig. 1 Study workflow
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adverse effects and the 2-year pelvic progression-free
survival, respectively.
Inclusion criteria
At initial registration
- Pathologically proven primary invasive uterine cervical
carcinoma. Squamous cell carcinoma, adenocarcinoma,
and adenosquamous cell carcinoma are eligible.
- Age between 20 and 75
- FIGO stage IB2, IIA2, IIB, IIIA, or IIIB
- Patients who will be treated with primary radiation
therapy and who received no treatment including
surgery, radiotherapy, or chemotherapy.
- Tumor width larger than 5 cm assessed by MRI taken
within four week before the start of
chemoradiotherapy.
- Eastern Cooperative Oncology Group (ECOG)
Performance Status of 0-2
- Adequate organ function:
a. Hemoglobin > 8.0 g/dl
b. Neutrophils > 2000 cells/μl
c. Platelets > 50,000 cells/μl
d. Serum ALT/AST ≤ 100 IU/L
e. Serum Total bilirubin ≤ 1.5 mg/dL
f. Serum creatinine ≤ 1.2 mg/dL and creatinine
clearance ≥ 60 ml/min
- No anticoagulant or antiplatelet medication
- No abnormal finding on electrocardiogram performed
14 days before study registration
- Written informed consent must be available before
study registration
At secondary registration
- Initial registration is already done
- Tumor width is larger than 4 cm assessed by MRI
taken within one week before initial session of HBT
- Eastern Cooperative Oncology Group (ECOG)
Performance Status of 0-2
- White blood cell > 2000 cells/μl and platelets > 50,000
cells/μl
Fig. 2 Overview of the protocol study
Fig. 3 Stages of the study
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Exclusion criteria
At initial registration
- Para-aortic lymph node metastasis with a short-axis
diameter of greater than 10 mm assessed by CT or
MRI
- Severe diabetes mellitus requiring continuous use of
insulin
- Uncontrollable severe hypertension
- Unstable angina which occurred within three weeks
or is recently exacerbating
- Transmural myocardial infarction within the last
6 months
- Simultaneous or metachronous (within 5 years)
double cancers excluding carcinoma in situ or
intramucosal tumor
- Active infectious disease to be treated
- Body temperature of 38 °C or more
- Psychiatric disease which hinders enrollment of
clinical trial
- Active ulcerative colitis or Chron’s disease
- Active SLE or systemic sclerosis
- Allergy to local anesthesia
- Positive for HBs antigen
At secondary registration
- FIGO IIIA disease the thickness of whose vaginal
involvement exceeds 5 mm at the time at 30-30.6 Gy/
15-17 fr and cannot be treated by ICBT alone
- Active infectious disease to be treated
- Body temperature of 38 °C or more
Ethical aspects, trial registration
The HBT trial is approved by the institutional ethical re-
view board of the National Cancer Center Hospital in
accordance with the ethical standards laid down in the
1964 Declaration of Helsinki and its later amendments.
The trial is registered with the UMIN (University Hos-
pital Medical Information Network in Japan) Clinical
Trials Registry, number UMIN000019081. Following is
the list of participating centers where the study has re-
ceived ethical approval: National Cancer Center Hos-
pital, Yamagata University Faculty of Medicine, Kagawa
Prefectural Central Hospital, Kawasaki Medical School,
Tokyo Medical and Dental University, Graduate School
of Medicine Chiba University, Institute of Health Biosci-
ences the University of Tokushima Graduate School,
Osaka Medical College, Research Center for Charged
Particle Therapy National Institute of Radiological Sci-
ences, Gunma University Graduate School of Medicine,
National Hospital Organization Fukuyama Medical Cen-
ter, Tokyo Rinkai Hospital, Tokyo Metropolitan Bokutoh
Hospital, and Toyota Memorial Hospital.
Therapy protocol
Figure 2 shows overview of protocol therapy. Weekly
CDDP (40 mg/m2) is administered concurrently with
EBRT. After 30-30.6 Gy in 15-17 fractions of whole pel-
vic radiotherapy, 24 Gy in 4 fractions of HBT and central
shield EBRT up to 50-50.4 Gy in 25-28 fractions are
started. If clinically swollen reginal pelvic lymph nodes
exist, 6-10 Gy in 3-5 fractions of boost EBRT is
performed.
The HBT methods
Figure 4 demonstrates the concept of the HBT. Figure 4a
is a schema of conventional ICBT. Thick solid line rep-
resents isodose line of the prescribed dose and tumor is
represented by shaded structure which extends left para-
metrium. Left distal part of parametrium is not ad-
equately covered by isodose line in Fig. 4a. Figure 4b is a
Fig. 4 Schema of the concept of the hybrid brachytherapy (HBT). Figure 4a is a schema of conventional intracavitary brachytherapy (ICBT) in
which tandem and ovoid are inserted in uterine cavity and vagina, respectively. Thick solid line represents isodose line of the prescribed dose.
Tumor is represented by shaded structure which extends left parametrium and notice that left distal part of parametrium is not adequately
covered by isodose line. Figure 4b is a schema of the HBT in which an additional interstitial needle is inserted to left parametrium covering of
which is not enough with conventional ICBT. Notice that isodose line now covers whole tumor completely
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Table 1 Definition of anatomical boundaries of high risk clinical target volume (HR-CTV) according to clinical stage
Caudal margin Cranial margin Lateral margin Posterior margin
IB At superior level of the ovoid. If uterine body involvement does
not exist, upper limit of uterine
cervix is cranial margin of HR-CTV
for IB disease. As the surrogate
structure of upper limit of uterine
cervix, recognize the level at which
uterine vessels first abut cervical
tissue or to point at which uterine
volume expands and uterine cavity
appears. Add 8 mm around
tandem superiorly to cover conical
cervical apex.
If direct uterine body involvement
exists, measure the distance
between fundus of the uterus and
most cranial part of the tumor on
MRI taken within one week before
first brachytherapy. Subtract this
distance from total length of the
uterus and contour HR-CTV from
the external os of the uterus until
this subtracted length.
Width of HR-CTV is equal to that
of uterine cervix.
-
IIA Modify contour inferiorly to cover
most inferior extent of vaginal
extension using information
derived from pelvic examination
and MRI as a reference.
If uterine body involvement does
not exist, upper limit of uterine
cervix is cranial margin of HR-CTV
for IB disease. As the surrogate
structure of upper limit of uterine
cervix, recognize the level at which
uterine vessels first abut cervical
tissue or to point at which uterine
volume expands and uterine cavity
appears. Add 8 mm around
tandem superiorly to cover conical
cervical apex.
If direct uterine body involvement
exists, measure the distance
between fundus of the uterus and
most cranial part of the tumor on
MRI taken within one week before
first brachytherapy. Subtract this
distance from total length of the
uterus and contour HR-CTV from
the external os of the uterus until
this subtracted length.
Width of HR-CTV is equal to that
of uterine cervix.
-
IIB If vaginal extension does not
exists, contour until the superior
level of the ovoid.
If vaginal extension exists, modify
contour inferiorly to cover most
inferior extent of vaginal
extension using information
derived from pelvic examination
and MRI as a reference.
If uterine body involvement does
not exist, upper limit of uterine
cervix is cranial margin of HR-CTV
for IB disease. As the surrogate
structure of upper limit of uterine
cervix, recognize the level at which
uterine vessels first abut cervical
tissue or to point at which uterine
volume expands and uterine cavity
appears. Add 8 mm around
tandem superiorly to cover conical
cervical apex.
If direct uterine body involvement
exists, measure the distance
between fundus of the uterus and
most cranial part of the tumor on
MRI taken within one week before
first brachytherapy. Subtract this
distance from total length of the
uterus and contour HR-CTV from
the external os of the uterus until
this subtracted length.
Measure the width of tumor by
the physical examination and/or
trans-rectal ultrasonography (TRUS)
and based on this length
determine the width of HR-CTV on
CT image.
Determine the width of HR-CTV
according to information of MRI
taken before brachytherapy. If
parametrial invasion is evident on
CT image, rely on CT information.
Caudal margin of parametrial
invasion is set at superior level of
the ovoid. Cranial margin of
parametrial invasion is set at the
cranial margin of cervix.
Contour HR-CTV posteriorly if
uterosacral ligament invasion
exists which is confirmed by pelvic
examination, CT, or MRI.
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schema of the HBT in which an additional interstitial
needle is inserted to left parametrium and this additional
needle can make isodose line cover the whole tumor
completely. High-risk clinical target volume (HR-CTV)
at HBT is delineated on CT taken with applicators in
place. Because of limited availability of MRI, dose calcu-
lation of HBT is based of CT in this study. Definition of
HR-CTV according to T stage is based on the contour-
ing guideline proposed by Viswanathan et al. [23] with
some modifications (Table 1). Table 2 summarizes dose
constraints of HBT and the goal is to deliver more than
6 Gy to HR-CTV D90 (dose covering 90 % of the HR-
CTV). In HBT, the diameter of hyper dose sleeve, which
is the isodose line of 200 % of the prescribed dose,
should be smaller than 1.5 cm and additional interstitial
needles are restricted to three needles in one side and at
most six needles in both sides. Tumors which cannot be
covered with HBT based on these rules should be
treated by ISBT alone with multiple interstitial needles.
Statistics
Study hypothesis and sample size
In modern technique of image-guided ISBT for locally
advanced uterine cervical cancer, the rate of grade 3 or
higher acute non-hematologic adverse effects was
Table 1 Definition of anatomical boundaries of high risk clinical target volume (HR-CTV) according to clinical stage (Continued)
IIIA Contour HR-CTV so that the
lowest extent of vaginal disease is
adequately covered. Urethral
meatus can be used as a
anatomical landmark to compare
CT, MRI, and physical examination.
If uterine body involvement does
not exist, upper limit of uterine
cervix is cranial margin of HR-CTV
for IB disease. As the surrogate
structure of upper limit of uterine
cervix, recognize the level at which
uterine vessels first abut cervical
tissue or to point at which uterine
volume expands and uterine cavity
appears. Add 8 mm around
tandem superiorly to cover conical
cervical apex.
If direct uterine body involvement
exists, measure the distance
between fundus of the uterus and
most cranial part of the tumor on
MRI taken within one week before
first brachytherapy. Subtract this
distance from total length of the
uterus and contour HR-CTV from
the external os of the uterus until
this subtracted length.
If no parametrial involvement
exists, contour until lateral edge of
the uterine cervix.
If parametrial involvement exists,
refer to the description in IIB.
Contour HR-CTV posteriorly if
uterosacral ligament invasion
exists which is confirmed by pelvic
examination, CT, or MRI.
IIIB If vaginal extension does not
exists, contour until the superior
level of the ovoid.
If invasion to upper 2/3 of vagina
exists, refer to the description in
IIA.
If invasion to lower 1/3 to vagina
exists, refer to the description in
IIIA.
If uterine body involvement does
not exist, upper limit of uterine
cervix is cranial margin of HR-CTV
for IB disease. As the surrogate
structure of upper limit of uterine
cervix, recognize the level at which
uterine vessels first abut cervical
tissue or to point at which uterine
volume expands and uterine cavity
appears. Add 8 mm around
tandem superiorly to cover conical
cervical apex.
If direct uterine body involvement
exists, measure the distance
between fundus of the uterus and
most cranial part of the tumor on
MRI taken within one week before
first brachytherapy. Subtract this
distance from total length of the
uterus and contour HR-CTV from
the external os of the uterus until
this subtracted length.
If parametrial involvement extends
until pelvic wall, extend the lateral
margin until pelvic wall such as
inner margin of the obturator
muscle or pelvic bone.
If no parametrial involvement
exists on contralateral side, refer to
the description in IB.
If parametrial involvement in
contralateral side does not extend
to pelvic wall, refer to the
description in IIB.
Contour HR-CTV posteriorly if
uterosacral ligament invasion
exists which is confirmed by
pelvic examination, CT, or MRI. If
fixation of uterosacral ligament
exists, extend HR-CTV to the sacral
bone.
Table 2 Dose constraints for organ at risk (OAR)
OAR Dose constraints
for each HBT
Dose constraints for combination
of EBRT and all HBTs (EQD2)
Rectum D2cc <6.15 Gy < 75 Gy
Bladder D2cc < 7.30 Gy < 90 Gy
Sigmoid D2cc < 6.15 Gy < 75 Gy
D2cc: most exposed 2 cc of tissue
EQD2: equivalent dose in 2 Gy fractions
Murakami et al. BMC Cancer  (2016) 16:640 Page 6 of 8
reported to be 6.9 % [24]. In the HBT, less applicators
are used compared to ISBT and dwell time of each appli-
cator is supposed to be longer in the HBT than in the
ISBT and complication is expected to be slightly higher
in HBT than in the ISBT according to longer dwell time
on each applicator. Therefore, threshold of the rate of
grade 3 or higher acute non-hematologic adverse effects
which are attributed to the HBT is set to be 10 % in this
trial. In phase I part, 20 patients will be enrolled and if
the rate of grade 3 or higher acute non-hematologic
adverse effects happen in more than 3 patients (>10 %),
the trial will be stopped.
In phase II part, it is hypothesized that HBT yields bet-
ter 2-year pelvic progression-free survival rate than con-
ventional ICBT for tumors which did not show good
response to whole pelvic radiation therapy. Historical
control data is cited from the publication of Pötter et al.
[22] which demonstrated that 2-year pelvic progression-
free survival rate of 64 % for patients with uterine cer-
vical cancer whose initial tumor size was larger than
5 cm and were treated with conventional ICBT. If the
lower margin of 90 % confidence interval of the 2-year
pelvic progression-free survival of the HBT trial is higher
than 64 %, the HBT is considered to be more effective
than conventional ICBT. In phase II part, the planned
sample size is 55 patients including 20 patients enrolled
in phase I part, which was calculated based on an ex-
pected 2-year pelvic progression-free survival of 80 %
and a threshold of 64.8 %, with a one-sided alpha error
of 0.05 and a beta error of 0.2.
Discussion
In the field of EBRT, there was a paradigm shift from two-
dimensional to three-dimensional image-based treatment
planning in last two decades. Likewise, in the field of
brachytherapy, the same paradigm shift occurred from
two-dimensional to three-dimensional image-based treat-
ment planning. Currently the EMBRACE study (https://
www.embracestudy.dk) [25] is running which investigates
feasibility and efficacy of image-guided adaptive brachy-
therapy in multi-institutional setting, however, in the EM-
BRACE study both the ICBT and the HBT are allowed to
be used without clear definition of which modality to
adapt. There exists no prospective trial focusing only on
the HBT. Therefore, this trial will elucidate the applica-
tion, safety, and efficacy of the HBT and will make a
cornerstone of the HBT for advanced uterine cervical
cancer radiation therapy.
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